Table 1.

Baseline characteristics and BoNT doses of BSP patients, HFS patients, and HC. Statistical differences between all three groups were analyzed using chi-squared test (sex), one-way ANOVA (age). The differences between BSP and HFS patient groups in BoNT dosage were tested by means of two-sample tests.

	BSP n = 13	HFS n = 13	HC n = 13	χ 2/ F/ t	p
Sex (M/F), n	5/8	4/9	8/5	χ2(2) = 2	0.2
Age, years (mean ± SD)	65 ± 6	60 ± 11	53 ± 7	F(2,36) = 2	0.1
BoNT_R, mU (mean ± SD)	38 ± 26.7	31.5 ± 35.7	–	t = 0.5	0.6
BoNT_L, mU (mean± SD)	37.3 ± 27.1	24.6 ± 34.6	–	t = 1	0.3

1 mU, mouse units of Botox equivalent; BoNT, botulinum neurotoxin; BSP, blepharospasm, HC, healthy controls; HFS, hemifacial spasm; M/F, male/female; N, number of subjects; R/L, right/left side of the face.